C5a Receptor Targeting in Neointima Formation After Arterial Injury in Atherosclerosis-Prone Mice
Authors:
- Kiril BidzhekovKBKiril Bidzhekov
- Sebastian F. MauseSMSebastian F. Mause
- Sakine SimsekyilmazSSSakine Simsekyilmaz
- Thomas PolakowskiTPThomas Polakowski
- Heiko HawlischHHHeiko Hawlisch
- J. Engelbert GessnerJGJ. Engelbert Gessner
- Alma ZerneckeAZAlma Zernecke
- Christian WeberCWChristian Weber
- 7 September 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 122 (10) , 1026-1036
Abstract
Background— Receptor binding of complement C5a leads to proinflammatory activation of many cell types, but the role of receptor-mediated action during arterial remodeling after injury has not been studied. In the present study, we examined the contribution of the C5a receptor (C5aR) to neointima formation in apolipoprotein E–deficient mice employing a C5aR antagonist (C5aRA) and a C5aR-blocking monoclonal antibody. Methods and Results— Mice fed an atherogenic diet were subjected to wire-induced endothelial denudation of the carotid artery and treated with C5aRA and anti-C5aR-blocking monoclonal antibody or vehicle control. Compared with controls, neointima formation was significantly reduced in mice receiving C5aRA or anti-C5aR-blocking monoclonal antibody for 1 week but not for 3 weeks, attributable to an increased content of vascular smooth muscle cells, whereas a marked decrease in monocyte and neutrophil content was associated with reduced vascular cell adhesion molecule-1. As assessed by immunohistochemistry, reverse transcription polymerase chain reaction, and flow cytometry, C5aR was expressed in lesional and cultured vascular smooth muscle cells, upregulated by injury or tumor necrosis factor-α, and reduced by C5aRA. Plasma levels and neointimal plasminogen activator inhibitor-1 peaked 1 week after injury and were downregulated in C5aRA-treated mice. In vitro, C5a induced plasminogen activator inhibitor-1 expression in endothelial cells and vascular smooth muscle cells in a C5aRA-dependent manner, possibly accounting for higher vascular smooth muscle cell immigration. Conclusions— One-week treatment with C5aRA or anti-C5aR-blocking monoclonal antibody limited neointimal hyperplasia and inflammatory cell content and was associated with reduced vascular cell adhesion molecule-1 expression. However, treatment for 3 weeks failed to reduce but rather stabilized plaques, likely by reducing vascular plasminogen activator inhibitor-1 and increasing vascular smooth muscle cell migration.Keywords
This publication has 46 references indexed in Scilit:
- The Intrinsic Complement Regulator Decay-Accelerating Factor Modulates the Biological Response to Vascular InjuryArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- C5a receptor‐deficient dendritic cells promote induction of Treg and Th17 cellsEuropean Journal of Immunology, 2010
- Complement component 5a (C5a)The International Journal of Biochemistry & Cell Biology, 2009
- Innate and adaptive immunity in atherosclerosisSeminars in Immunopathology, 2009
- Complement 5a Receptor Inhibition Improves Renal Allograft SurvivalJournal of the American Society of Nephrology, 2008
- Role of Smooth Muscle Cells in the Initiation and Early Progression of AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Locally Produced Complement Fragments C5a and C3a Provide Both Costimulatory and Survival Signals to Naive CD4+ T CellsImmunity, 2008
- C1-Esterase Inhibitor Protects Against Neointima Formation After Arterial Injury in Atherosclerosis-Prone MiceCirculation, 2008
- Function, structure and therapeutic potential of complement C5a receptorsBritish Journal of Pharmacology, 2007
- Inhibition of Complement Component C3 Reduces Vein Graft Atherosclerosis in Apolipoprotein E3–Leiden Transgenic MiceCirculation, 2006